Mpox: Africa’s response is obstructed by manufacturer’s failure to share vaccine technology and unfair pricing, says campaign group
BMJ 2024; 387 doi: https://doi.org/10.1136/bmj.q2174 (Published 03 October 2024) Cite this as: BMJ 2024;387:q2174- Gilbert Nakweya
- Nairobi
Access to urgently needed mpox vaccines in Africa is being hampered by the refusal of leading vaccine manufacturer Bavarian Nordic to share its technology and disclose its prices, a consumer rights group has claimed.
Public Citizen says that the Denmark headquartered company “has done far too little to enable access to its vaccine outside of wealthy countries” despite getting public funding.1
The modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is manufactured and supplied by Bavarian Nordic as Jynneos, Imvamune, or Imvanex to prevent mpox and smallpox. Shortly after the World Health Organization declared mpox a public health emergency of international concern on 14 August, Bavarian Nordic and the Africa Centres for Disease Control and Prevention announced a partnership to ensure equitable access to the vaccine. Bavarian Nordic promised to increase manufacturing and supply to Africa, as well as enhancing the “manufacturing …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.